| CTRI Number |
CTRI/2025/12/099471 [Registered on: 19/12/2025] Trial Registered Prospectively |
| Last Modified On: |
18/12/2025 |
| Post Graduate Thesis |
No |
| Type of Trial |
Observational |
|
Type of Study
|
Prospective |
| Study Design |
Single Arm Study |
|
Public Title of Study
|
Evaluation of retinal images taken for the participants and Diabetic Retinopathy AI performance among the new automated non-mydriatic fundus camera and standard fundus camera |
|
Scientific Title of Study
|
Evaluation of Retinal Image Quality, Lesion Detection and Diabetic Retinopathy AI Performance Using a New Automated Non-Mydriatic Tabletop Fundus Camera: A Prospective Validation Against a Reference Standard System |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Manavi D Sindal |
| Designation |
HOD Retina and Vitreous Services |
| Affiliation |
Aravind Eye Hospital |
| Address |
Room No. 22, B BLOCK, First floor Cuddalore main road, Thavalakuppam Pondicherry PONDICHERRY 605007 India |
| Phone |
09884081417 |
| Fax |
|
| Email |
manavi@aravind.org |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Manavi D Sindal |
| Designation |
HOD Retina and Vitreous Services |
| Affiliation |
Aravind Eye Hospital |
| Address |
Room No. 22, B BLOCK, First floor Cuddalore main road, Thavalakuppam
PONDICHERRY 605007 India |
| Phone |
09884081417 |
| Fax |
|
| Email |
manavi@aravind.org |
|
Details of Contact Person Public Query
|
| Name |
Dr Manavi D Sindal |
| Designation |
HOD Retina and Vitreous Services |
| Affiliation |
Aravind Eye Hospital |
| Address |
Room No. 22, B BLOCK, First floor Cuddalore main road, Thavalakuppam
PONDICHERRY 605007 India |
| Phone |
09884081417 |
| Fax |
|
| Email |
manavi@aravind.org |
|
|
Source of Monetary or Material Support
|
|
|
Primary Sponsor
|
| Name |
Remidio Innovative Solutions Pvt Ltd |
| Address |
No, 1-51-2/12, Vacuum Techniques Compound, 1st Cross Rd, Phase-I, Peenya, Bengaluru, Karnataka 560058 |
| Type of Sponsor |
Other [Medical Device ] |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Manavi D Sindal |
Aravind Eye Hospital |
Cuddalore main road
Thavalakuppam
Pondicherry Pondicherry PONDICHERRY |
9884081417
manavi@aravind.org |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutional Ethics Committee Aravind Eye Hospital |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: H350||Background retinopathy and retinalvascular changes, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Nil |
Nil |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
80.00 Year(s) |
| Gender |
Both |
| Details |
1. All subjects above 18 years of age and ready to give written consent |
|
| ExclusionCriteria |
| Details |
1. significant media opacities (e.g., advanced cataract, corneal opacity)
2. inability to fixate (e.g., nystagmus, amblyopia)
3. active ocular infection or post-operative status
4. hypersensitivity to light, or contraindications to pharmacological dilation (e.g., angle-closure glaucoma)
|
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
Proportion of gradable vs. ungradable images per device
• Level of agreement in image quality between devices
• AI performance metrics per device
• Agreement or discordance in DR detection between devices
• InstaZ performance in retinal lesion detection
• Agreement in gradability pre- vs. post-dilation
• Repeatability of InstaZ image outputs
|
Baseline |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| NIL |
NIL |
|
|
Target Sample Size
|
Total Sample Size="600" Sample Size from India="600"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
15/01/2026 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="0" Months="6" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Open to Recruitment |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Background
High-quality fundus imaging is critical for effective screening and diagnosis of retinal diseases, particularly diabetic retinopathy. Image quality assessment IQA plays a vital role in ensuring diagnostic accuracy and can be evaluated using both objective device-based and subjective human evaluator-based methods. Subjective assessment remains the most trusted approach, especially since clinical interpretation depends on human review.In this study, we will evaluate and compare the study device against two reference standard non-mydriatic fundus imaging systems
Study device Remidio InstaZ Non-Mydriatic Fundus Camera Reference standard Topcon NW400 fundus camera system. Additional Reference Standard device for AI evaluation, objective 2 Remidio Fundus-On-Phone NM10 FOP NM-10
The FOP NM-10 is a compact, smartphone-based, non-mydriatic camera that offers a 40° field of view and is designed for accessibility, ease of use, and cost-effectiveness. It includes an in-built image quality assessor and is equipped with offline AI algorithms for detecting diabetic retinopathy and glaucoma. These AI models have demonstrated strong diagnostic performance, with validated sensitivity and specificity rates of up to 100 percentage, 93.4percentage, and 88.4percentage, 85.4percentage for DR and glaucoma, respectively. The InstaZ study device, in contrast, is a high-resolution tabletop fundus camera equipped with features such as 3D auto-tracking, auto-capture, and a wider 45 degree field of view. It allows imaging without dilation or dark room conditions and supports imaging enhancing diagnostic versatility. This device does not consists of an inbuilt Artificial Intelligence AI for detecting DR.
The primary objective of the study is to assess and compare the image quality of fundus photographs captured using an automated tabletop non-mydriatic fundus camera Remidio InstaZ and reference standard fundus camera system Topcon NW400. Another primary objective is to evaluate the device agnostic performance of MediosHI DR artificial AI algorithm integrated on FOP NM10 when applied to the novel study device images in diabetic individuals by running the InstaZ images through the same AI algorithm in script form.
Methodology Consecutive adult patients Greater than 18 years attending the general ophthalmology unit and willing to provide informed consent, will be recruited. Participants must have good fixation and be cooperative during imaging. Exclusion criteria include significant media opacities e.g., advanced cataract, corneal opacity, inability to fixate e.g., nystagmus, amblyopia, active ocular infection or post-operative status, hypersensitivity to light, or contraindications to pharmacological dilation e.g., angle-closure glaucoma. All participants will undergo a standardized eye examination including history, vision assessment, refraction, slit-lamp evaluation, and dilated fundus examination. Following dilation, all the participants will undergo cataract grading if any using LOCS III classification system by trained ophthalmologist.
|